We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Avacta
FY25 results: clinical data will define the coming yearAvacta
AVA6103 (FAP-Exd) starts Phase Ia FOCUS clinical trialAvacta
£10m raise extends runway beyond FAP-EXd catalystsHUTCHMED
Momentum in revenues, ATTC development promiseAvacta
Innovative AI analysis comparing pre|CISION PDCs to ADCsScancell
H126: solid iSCIB1+ data underpins planned progressScancell
FDA clears global Phase III trial for iSCIB1+Avacta
pre|CISION prospects buildHUTCHMED
A month of notable pipeline progressAvacta
FAP-Dox Phase Ib results confirm efficacy in SGC